Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer. Pluvicto™ ...
Pluvicto (lutetium [177Lu] vipivotide tetraxetan), which won FDA approval in 2022, is fast becoming the dominant RLT for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback